Allon Therapeutics Inc.
TSX : NPC

Allon Therapeutics Inc.

November 07, 2005 12:40 ET

Allon Selected as One of 'Canada's Top 10 Life Sciences' for Investment and Partnership Prospects

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Nov. 7, 2005) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company™, today announced that it has been chosen as one of Canada's top 10 life science companies by an independent selection jury in the Top 10 Life Science Companies Competition, a national awards program hosted by the Ottawa Life Sciences Council. The jury, comprised of senior venture capitalists from across the US and Canada, is recognizing ten world-class companies that could compete globally and offer the best investment and partnership prospects.

"Allon is delighted to receive this recognition," said Allon's President and Chief Executive Officer Gordon McCauley. "This award is a tribute to our team, which has successfully advanced Allon's widely-validated clinical compounds in a very short period of time."

Allon will be presented with the Top 10 Life Science Companies 2005 award on November 28 in Ottawa at BioNorth, Canada's international biotechnology and life sciences conference and exhibition.

For further information about Canada's Top 10 Life Science Companies Competition, please visit www.bionorth.ca.

About Allon

Allon Therapeutics Inc. is a development-stage Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as stroke, traumatic brain injury, Alzheimer's, multiple sclerosis and neuropathy. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company™) and based in Vancouver.


Contact Information